|Treatments:||Chemotherapy||Hospital:||San Camillo and Forlanini Hospitals|
This phase 3 study involved patients with muscle-invasive urothelial carcinoma of the bladder who had previous radical cystectomy surgery. Patients were divided into two separate treatment groups. Group A consisted of 141 patients with a median age of 61 years, and 79% were male. Group B consisted of 143 patients with a median age of 61 years, and 80% were male.
Patients in group A received chemotherapy with gemcitabine, cisplatin, methotrexate, vinblastine, and doxorubicin immediately after their surgery.
Patients in group B received deferred chemotherapy with gemcitabine, cisplatin, methotrexate, vinblastine, and doxorubicin at the time of cancer relapse following surgery.
There was one treatment-related death due to sepsis (infection) in group A. Grade 4 neutropenia and low platelet counts were also reported.
There was one treatment-related death due to unknown causes in group B. Grade 4 neutropenia, low platelet count, and liver toxicity were also reported.
The median overall survival times for groups A and B were 80.88 and 55.2 months, respectively.
This study was partially supported by the Eli Lilly pharmaceutical company.
Correspondence: Dr. Cora N Sternberg; email: email@example.com